Author’s Reply to the Letter to the Editor by Fountoulakis

References
1 Ghajar A, Neishabouri S, Velayati N. et al. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. Pharmacopsychiatry 2016;
2 Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. British Medical Journal 1998; 316: 201
3 Zimmerman M, Martinez JH, Young D. et al. Severity classification on the Hamilton depression rating scale. Journal of affective disorders 2013; 150: 384-388
4 Rush A, First M, Blackar D. Handbook of Psychiatric Measures. American Psychiatric Publishing. Inc; Washington: 2008
5 Geromichalos GD, Lamari FN, Papandreou MA. et al. Saffron as a source of novel acetylcholinesterase inhibitors: Molecular docking and in vitro enzymatic studies. Journal of agricultural and food chemistry 2012; 60: 6131-6138
6 Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. Journal of affective disorders 2017; 207: 188-196
7 Ravindran AV, Balneaves LG, Faulkner G. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 5. complementary and alternative medicine treatments. The Canadian Journal of Psychiatry 2016; 61: 576-587